Cargando…

Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy

BACKGROUND: Duchenne muscular dystrophy (DMD) is a fatal disease for which no cure is available. Clinical trials have shown to be largely underpowered due to inter‐individual variability and noisy outcome measures. The availability of biomarkers able to anticipate clinical benefit is highly needed t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Signorelli, Mirko, Ayoglu, Burcu, Johansson, Camilla, Lochmüller, Hanns, Straub, Volker, Muntoni, Francesco, Niks, Erik, Tsonaka, Roula, Persson, Anja, Aartsma‐Rus, Annemieke, Nilsson, Peter, Al‐Khalili Szigyarto, Cristina, Spitali, Pietro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113516/ https://www.ncbi.nlm.nih.gov/pubmed/31881125 http://dx.doi.org/10.1002/jcsm.12517

Ejemplares similares

Blood-derived biomarkers correlate with clinical progression in Duchenne muscular dystrophy
por: Strandberg, Kristin, et al.
Publicado: (2020)

Tracking disease progression non‐invasively in Duchenne and Becker muscular dystrophies
por: Spitali, Pietro, et al.
Publicado: (2018)

Orthogonal proteomics methods warrant the development of Duchenne muscular dystrophy biomarkers
por: Johansson, Camilla, et al.
Publicado: (2023)

Longitudinal metabolomic analysis of plasma enables modeling disease progression in Duchenne muscular dystrophy mouse models
por: Tsonaka, Roula, et al.
Publicado: (2020)

Circulating Biomarkers for Duchenne Muscular Dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2015)

Multiomic characterization of disease progression in mice lacking dystrophin
por: Signorelli, Mirko, et al.
Publicado: (2023)

Biomarkers of Duchenne muscular dystrophy: current findings
por: Szigyarto, Cristina Al-Khalili, et al.
Publicado: (2018)

Penalized regression calibration: A method for the prediction of survival outcomes using complex longitudinal and high‐dimensional data
por: Signorelli, Mirko, et al.
Publicado: (2021)

Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies
por: Ayoglu, Burcu, et al.
Publicado: (2014)

Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne
por: Lourbakos, A., et al.
Publicado: (2017)

Plasma lipidomic analysis shows a disease progression signature in mdx mice
por: Tsonaka, Roula, et al.
Publicado: (2021)

TCTEX1D1 is a genetic modifier of disease progression in Duchenne muscular dystrophy
por: Spitali, Pietro, et al.
Publicado: (2020)

The importance of genetic diagnosis for Duchenne muscular dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2016)

Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants
por: van den Bergen, Janneke C, et al.
Publicado: (2015)

FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2017)

Cross‐sectional serum metabolomic study of multiple forms of muscular dystrophy
por: Spitali, Pietro, et al.
Publicado: (2018)

Imperatives for DUCHENNE MD: a Simplified Guide to Comprehensive Care for Duchenne Muscular Dystrophy
por: Kinnett, Kathi, et al.
Publicado: (2015)

Rimeporide as a ﬁrst- in-class NHE-1 inhibitor: Results of a phase Ib trial in young patients with Duchenne Muscular Dystrophy
por: Previtali, Stefano C., et al.
Publicado: (2020)

Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2017)

Spatial transcriptomics reveal markers of histopathological changes in Duchenne muscular dystrophy mouse models
por: Heezen, L.G.M., et al.
Publicado: (2023)

The Effect of 6-Thioguanine on Alternative Splicing and Antisense-Mediated Exon Skipping Treatment for Duchenne Muscular Dystrophy
por: Verhaart, Ingrid E. C., et al.
Publicado: (2012)

The Dilemma of Choice for Duchenne Patients Eligible for Exon 51 Skipping The European Experience
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2023)

Quantifying the burden of caregiving in Duchenne muscular dystrophy
por: Landfeldt, Erik, et al.
Publicado: (2016)

Negative Binomial mixed models estimated with the maximum likelihood method can be used for longitudinal RNAseq data
por: Tsonaka, Roula, et al.
Publicado: (2020)

Tumor Necrosis Factor Receptor SF10A (TNFRSF10A) SNPs Correlate With Corticosteroid Response in Duchenne Muscular Dystrophy
por: Passarelli, Chiara, et al.
Publicado: (2020)

Compliance to Care Guidelines for Duchenne Muscular Dystrophy
por: Landfeldt, Erik, et al.
Publicado: (2015)

Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2007)

Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis
por: Landfeldt, Erik, et al.
Publicado: (2016)

DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy: A Multi-institution Meta-analysis With Implications for Clinical Trials
por: Muntoni, Francesco, et al.
Publicado: (2023)

Peripheral blood transcriptome profiling enables monitoring disease progression in dystrophic mice and patients
por: Signorelli, Mirko, et al.
Publicado: (2021)

CRISPR applications for Duchenne muscular dystrophy: From animal models to potential therapies
por: Chey, Yu C. J., et al.
Publicado: (2022)

Case Report: The Genetic Diagnosis of Duchenne Muscular Dystrophy in the Middle East
por: Alghamdi, Fouad, et al.
Publicado: (2021)

Assessment of Behavioral Characteristics With Procedures of Minimal Human Interference in the mdx Mouse Model for Duchenne Muscular Dystrophy
por: Engelbeen, Sarah, et al.
Publicado: (2021)

Dystromirs as Serum Biomarkers for Monitoring the Disease Severity in Duchenne Muscular Dystrophy
por: Zaharieva, Irina T., et al.
Publicado: (2013)

The burden of Duchenne muscular dystrophy: An international, cross-sectional study
por: Landfeldt, Erik, et al.
Publicado: (2014)

A multicenter comparison of quantification methods for antisense oligonucleotide-induced DMD exon 51 skipping in Duchenne muscular dystrophy cell cultures
por: Hiller, Monika, et al.
Publicado: (2018)

Transition from childhood to adulthood in Duchenne muscular dystrophy (DMD)
por: Rodger, Sunil, et al.
Publicado: (2012)

Assessment of the feasibility of exon 45–55 multiexon skipping for duchenne muscular dystrophy
por: van Vliet, Laura, et al.
Publicado: (2008)

Health‐related quality of life in patients with Duchenne muscular dystrophy: a multinational, cross‐sectional study
por: Landfeldt, Erik, et al.
Publicado: (2015)

Natural disease history of the D2-mdx mouse model for Duchenne muscular dystrophy
por: van Putten, Maaike, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7cq50l07fdobkdkbjm22jpkl6o